RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc
← Directory

Protocol Single compound

KPV

α-MSH(11-13)

C-terminal α-MSH tripeptide referenced in anti-inflammatory signaling research.

Compare side by side →
Tissue Repair

Laboratory reference · in vitro research data

Research vial sizes
10 mg
Dosing data
Not listed — reference entry covers vial concentration only.
Storage
Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.

Reconstitution concentrations

Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.

VialBAC watermg/mLmg per 10 u
10 mg1 mL101
10 mg2 mL50.5
10 mg3 mL3.330.333

Calculate your vial

Add reminder

Enter your own schedule. Saved only on this device — never sent anywhere.

Research use only — educational reference, not medical advice. This line is added to every reminder.

Works with iPhone Calendar, Google Calendar and Outlook.

Saved only in this browser. My reminders

Inputs
mg
mL
1 mg = 1,000 mcg
mg

Draw to

—units

= — mL on a U-100 syringe

Concentration
—
Per unit
—
Doses / vial
—
Syringe
01020304050607080901000.0u
U-100 · 100 units (1 mL)2 unit per line

Research dossier · published literature summary

01

Mechanism of action

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH. It is taken up by the PepT1 transporter in gut and immune cells and inhibits NF-κB and MAP kinase inflammatory signalling.

02

Observed research endpoints

  • In mouse colitis models, oral KPV reduced intestinal inflammation and pro-inflammatory cytokine expression.
  • An engineered oral KPV conjugate reached 3.8-fold higher colon levels than free KPV in colitic mice and was also anti-inflammatory in acute lung injury.

03

Regulatory & safety context

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Evidence is from cell and mouse studies; no human trials are cited.

04

Citations

  1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.2008-01Preclinical study (cell, mouse)Read paper ↗
  2. Cheng J, et al. Inflammation-triggered self-immolative conjugates enable oral peptide delivery. Sci Adv. 2026;12:eaea2989.2026-01Preclinical study (mouse)Read paper ↗

Keep exploring

Found in these stacks & blends

BlendKLOWBlendTri-HealReference

Where researchers source it

Listings are provided for reference — always verify the latest third-party COA before purchasing.

Medvinci Research

See site

Featured supplier · third-party tested, COA published per batch

View product View COA

Supplier B

TBD

Placeholder — details coming soon

View productView COA

Supplier C

TBD

Placeholder — details coming soon

View productView COA